Cannabinoid and Receptor Modulator Compositions for Neurologic Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new pharmaceutical compositions and methods to effectively treat inflammatory, neurologic, and vascular conditions, particularly those associated with the activation of the NLRP3-inflammasome complex.
Innovation Solution
The use of a combination of a cannabinoid and a modulator compound that acts as an NMDA receptor modulator, a 5-HT3 receptor modulator, a nicotinic acetylcholine receptor modulator, a dopamine D2 receptor modulator, or a sigma-1 receptor modulator to treat inflammatory, neurologic, and vascular conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional palliative treatment options are used, then relief from symptoms is provided, but the underlying inflammatory and neurologic conditions are not effectively treated
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism (NLRP3-inflammasome activation) from the complex inflammatory cascade, using selective inhibitors to block this specific pathway rather than using broad-spectrum anti-inflammatory agents. This approach removes the harmful inflammatory response at its source while preserving other physiological functions.
Solution Approach 2:
The patent introduces pharmaceutical compositions containing specific anti-inflammatory agents and neuroprotective compounds as intermediaries that mediate between the inflammatory stimulus and the tissue damage outcome. These compounds act as biochemical intermediaries to interrupt the pathological cascade and protect neurological tissue.
2Adaptability or versatility
If broad-spectrum anti-inflammatory treatments are used, then general inflammation is reduced, but specific neurologic and vascular conditions are not effectively addressed
Solution Approach 1:
The patent applies local quality by designing treatments that specifically target neurological and vascular tissues affected by inflammation. The pharmaceutical compositions are formulated to achieve selective distribution and action in neurologic tissues, providing localized therapeutic effects while maintaining broad anti-inflammatory activity where needed.
Solution Approach 2:
The patent employs parameter changes by adjusting the chemical structure, dosage, and administration parameters of anti-inflammatory agents to optimize their effectiveness for specific neurologic conditions. This includes modifying drug properties to enhance blood-brain barrier penetration and targeting specific inflammatory pathways involved in neurologic damage.
3Ease of operation
If multiple separate treatments are administered for different symptoms, then various symptoms may be addressed, but treatment complexity and administration burden increase
Solution Approach 1:
The patent merges multiple therapeutic agents into single pharmaceutical compositions or combination therapies. The formulations combine anti-inflammatory agents, neuroprotective compounds, and vascular protective agents into integrated treatments that address multiple aspects of the condition simultaneously, reducing administration burden while maintaining comprehensive efficacy.
Data Source
AI summary
Described are pharmaceutical compositions for treating an inflammatory condition, a neurologic condition and/or a vascular condition, the composition including i) a cannabinoid and ii) a modulator compound that acts as one or more of an NMDA receptor modulator, a 5-HT3 receptor modulator, a nicotinic acetylcholine receptor modulator, a dopamine D2 receptor modulator, or a sigma-1 receptor modulator. Further described are methods of treating inflammatory, neurologic and/or vascular conditions.